Checkpoint Inhibitor Induced Glomerulonephritis.

e15083Background: Immune checkpoint (ICP) inhibitors, anti-CTLA-4 (Ipilimumab) and anti-PD-1 (Nivolumab and Pembrolizumab) have revolutionized treatment options for many types of cancers. Adverse events associated with ICP inhibitors are mainly due to uninhibited immune system inducing autoimmune diseases. Literature on nephrotoxicity of these novel agents is limited. Acute tubulointerstitial nephritis (ATIN) is the most commonly described kidney injury secondary to ICP inhibitors. In this abstract we are highlighting glomerulonephritis (GN) induced by ICP inhibitors. Methods: We retrospectively reviewed all kidney biopsies performed at MDA (2008-2017). We identified 10 cases with ICP induced nephrotoxicity. Results: We present 10 cases of biopsy proven nephrotoxicity during treatment with ICP inhibitors. Malignancies associated with the cases were as following: Renal cell carcinoma (n = 2), smoldering myeloma (n = 2), melanoma (n = 2), chondroma (n = 1), bladder cancer (n = 1), Lymphoma (n = 1) and lung ...